Comment
doi: 10.1016/S1470-2045(23)00474-6.
Tumor Treating Fields therapy in metastatic non-small-cell lung cancer
Affiliations
- PMID: 38039995
- DOI: 10.1016/S1470-2045(23)00474-6
Item in Clipboard
Comment
Tumor Treating Fields therapy in metastatic non-small-cell lung cancer
Lancet Oncol.
2023 Dec.
No abstract available
Conflict of interest statement
AA received consulting fees from Amgen, AstraZeneca, Roche, Astellas, Takeda, BMS, MSD, Pfizer, Merck, and Novartis. Additionally, AA received payments or honoraria for educational events from Amgen and Novartis. TO declares no competing interests.
Comment in
-
Tumor Treating Fields therapy in metastatic non-small-cell lung cancer - Authors' reply.Lancet Oncol. 2023 Dec;24(12):e454. doi: 10.1016/S1470-2045(23)00584-3. Lancet Oncol. 2023. PMID: 38039996 No abstract available.
Comment on
-
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.Lancet Oncol. 2023 Sep;24(9):1002-1017. doi: 10.1016/S1470-2045(23)00344-3. Lancet Oncol. 2023. PMID: 37657460 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
